Top Medical Journal Demands More Trial Data From Drug Cos.

Law360, New York (November 1, 2012, 5:55 PM EDT) -- The British Medical Journal announced Monday that it would only publish studies by researchers and drugmakers that make patient-level clinical trial data available, joining GlaxoSmithKline PLC and European regulators in a recent push toward greater drug and medical device data transparency.

Beginning in January, study authors must commit to making “relevant anonymized patient-level data available on reasonable request” for their trials to be published in the journal, Editor-in-Chief Fiona Godlee wrote in an editorial.

The European Medicines Agency announced in July that it planned to require...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.